I am treating a patient with





Dose Modification Decision Charts



CLL

CLL Dose Modification Decision Chart

*GCSF can be considered in select patients depending on regimen


DOSE REDUCTIONS FOR TLS AND OTHER TOXICITIES
Dose at Interruption Restart Dose
400mg 300mg
300mg 200mg
200mg 100mg
100mg 50mg
50mg 20mg
20mg 10mg
*Any dose interruption lasting more than 1 week during ramp up phase, or more than 2 weeks after completion of ramp up, reassess for TLS to determine if reinitiation with reduced dose is warranted
*Consider discontinuing venetoclax in patients who require dose reductions to < 100mg for more than 2 weeks

AML

AML Dose Modification Decision Chart

*For Grade 3-4 non-hematologic toxicities, interrupt venetoclax if toxicity not resolved with supportive care. Upon resolution to Grade 1 or baseline, resume venetoclax at same dose.

*Bone marrow assessment recommended at the end of Cycle 1 to measure response. After achieving remission, treatment should be delayed until counts recover